Evotec SE, DE0005664809

Evotec stock gains 4.00% to EUR 2.86 premarket

Published on 11/19/2026 at 08:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec develops drug candidates and drug-discovery technologies for pharmaceutical and biotechnology partners. On Xetra, the stock closed at EUR 2.75 on Wednesday, November 18, 2026.

Evotec business and market position

  • Evotec develops drug candidates and drug-discovery technologies for pharmaceutical and biotechnology partners.
  • The company combines Shared R&D with its Just - Evotec Biologics business.
Evotec SE, DE0005664809, Illustration mit AI erstellt.

Evotec stock starts Thursday higher

Evotec stock traded at EUR 2.86 on Lang & Schwarz at 08:11 CET on Thursday, November 19, 2026, 4.00 percent above the Xetra close of Wednesday, November 18, 2026, at EUR 2.75.

Evotec develops drug candidates and drug-discovery technologies for pharmaceutical and biotechnology partners. Its business combines Shared R&D with Just - Evotec Biologics, according to Evotec Investor Relations.

The broader German market can be followed through current market reports.

More news and analyses on Evotec stock.

Disclaimer...
en | DE0005664809 | EVOTEC SE | boerse | 70534393 | bgmi